Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.
about
Role of positron emission tomography for the monitoring of response to therapy in breast cancerDo clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?Correlation between the Uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-AnalysisUltrasound-Guided Diffuse Optical Tomography for Predicting and Monitoring Neoadjuvant Chemotherapy of Breast Cancers: Recent Progress.18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis.¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.Present and future role of FDG-PET/CT imaging in the management of breast cancer.¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials.Basal ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography as a prognostic biomarker in patients with locally advanced breast cancer.Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts.Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients.Is (18)FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer?Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.Concerning pretreatment ¹⁸F-FDG PET/CT imaging in patients with large or locally advanced breast cancer.Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
P2860
Q28080621-7FB16D5A-1251-42C9-9522-986B06007B6FQ33576007-94380A47-FAE3-4B81-866F-0C1C0855104EQ35650841-008DBBCB-7ED4-459B-A4FB-6E89E241F42DQ37324851-71EFABB0-CD0C-49A8-91A1-964212DE9574Q37566580-9135026F-508C-45D1-AE71-D226A0834B41Q37582345-0B08771B-AA3A-46DE-A6BF-D0996A2A2226Q38687620-051D4F3F-A7AD-4F39-8418-8369C5AC9B8AQ38693888-E4E53FAD-757A-48F1-8CFD-711F9F6B68C9Q42479479-D381C6AE-6EB0-44C6-ACCC-FA8F88E00E2BQ42497866-E8B74297-56EB-4DF4-B702-44019C2F8DA3Q43082312-CFC4857E-9DB4-4C39-815E-66E9DD91226FQ48047542-55C44B25-0579-437B-AD5B-98C50628D829Q51727954-AAF21767-DB91-4A83-B8F8-9AEC7991E2D6Q53008476-120A5789-1FAA-417E-8CD0-48482F755260Q53396296-A75ED724-B8B0-48C1-A593-25F47F5FD802Q59129064-E0D1A4A7-C39A-42B5-9DC3-324DD72A9F2D
P2860
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Prognostic relevance at 5 year ...... l HER2-negative breast cancer.
@en
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using
@nl
type
label
Prognostic relevance at 5 year ...... l HER2-negative breast cancer.
@en
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using
@nl
prefLabel
Prognostic relevance at 5 year ...... l HER2-negative breast cancer.
@en
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using
@nl
P2093
P2860
P1476
Prognostic relevance at 5 year ...... l HER2-negative breast cancer.
@en
P2093
Alexandre Cochet
Alina Berriolo-Riedinger
Charles Coutant
Céline Charon-Barra
François Brunotte
Inna Dygai-Cochet
Isabelle Desmoulins
Michel Toubeau
Mélanie Gauthier
Olivier Humbert
P2860
P2888
P304
P356
10.1007/S00259-013-2616-3
P577
2013-11-21T00:00:00Z